Medherant: Difference between revisions
Added {{self-published}} tag to article (TW) |
cleanup and edit for WP:NPOV |
||
| Line 12: | Line 12: | ||
}} | }} | ||
'''Medherant Ltd''' is a British [[pharmaceutical company]] currently based in Coventry. The company | '''Medherant Ltd''' is a British [[pharmaceutical company]] currently based in [[Coventry]]. The company develops [[over-the-counter]] (OTC) and prescription [[transdermal patch]]es for [[drug delivery]]. | ||
==History== | ==History== | ||
Medherant Ltd was founded as a university spin-off by Professor David Haddleton and the [[University of Warwick]] in 2015 for the purpose of commercialisation of a novel drug delivery system. | Medherant Ltd was founded as a [[university spin-off]] by Professor David Haddleton and the [[University of Warwick]] in 2015 for the purpose of commercialisation of a novel drug delivery system. | ||
Started as a research project in | Started as a research project in Haddleton Group at the University of Warwick in 2013, the company operates at the [[University of Warwick Science Park]] since March 2015 after securing an investment from the [[Mercia Fund Management]] in 2014. | ||
== | ==Research== | ||
Using its | Using its research in [[bioadhesive]]s and [[polymer chemistry]], the company intends to introduce patches in 2018 which are able to deliver drugs via the trans[[epidermal]] route.<ref>{{cite web |url=https://www2.warwick.ac.uk/newsandevents/pressreleases/researchers_create_world146s/ |title=Researchers create World’s first ibuprofen patch - delivering pain relief directly through skin |publisher=University of Warwick |accessdate=October 16, 2016}}</ref> Medherant's TEPI patch technology aims to provide controlled delivery of the correct dose, and better patient experience. The technology is also designed to be environmentally and economically efficient, requiring no [[solvent]]s for the fabrication process.<ref>{{cite web |url=https://http://www.medherant.co.uk/about-us |title=Medherant is developing a first-in-class transdermal drug delivery patch for prescription and OTC medicines |publisher=Medherant Ltd |accessdate=October 16, 2016}}</ref> | ||
Medherant is also developing [[transdermal analgesic patch]]es for pain relief, based on [[nonsteroidal anti-inflammatory drugs]] (NSAIDs), e.g. [[ibuprofen]], [[lidocaine]], [[diclofenac]] and [[methyl salicylate]], with plans to release its first product on the market by 2018. | |||
Medherant is developing pain | |||
==References== | ==References== | ||
{{reflist}} | {{reflist}} | ||
==External links== | |||
* [http://www.haddleton.org Haddleton Group] | |||
[[Category:Companies based in Coventry]] | [[Category:Companies based in Coventry]] | ||
[[Category:Pharmaceutical companies of the United Kingdom]] | [[Category:Pharmaceutical companies of the United Kingdom]] | ||
Revision as of 15:44, 16 October 2016
Template:Self-published Template:Infobox company
Medherant Ltd is a British pharmaceutical company currently based in Coventry. The company develops over-the-counter (OTC) and prescription transdermal patches for drug delivery.
History
Medherant Ltd was founded as a university spin-off by Professor David Haddleton and the University of Warwick in 2015 for the purpose of commercialisation of a novel drug delivery system. Started as a research project in Haddleton Group at the University of Warwick in 2013, the company operates at the University of Warwick Science Park since March 2015 after securing an investment from the Mercia Fund Management in 2014.
Research
Using its research in bioadhesives and polymer chemistry, the company intends to introduce patches in 2018 which are able to deliver drugs via the transepidermal route.[1] Medherant's TEPI patch technology aims to provide controlled delivery of the correct dose, and better patient experience. The technology is also designed to be environmentally and economically efficient, requiring no solvents for the fabrication process.[2]
Medherant is also developing transdermal analgesic patches for pain relief, based on nonsteroidal anti-inflammatory drugs (NSAIDs), e.g. ibuprofen, lidocaine, diclofenac and methyl salicylate, with plans to release its first product on the market by 2018.
References
- ↑ "Researchers create World’s first ibuprofen patch - delivering pain relief directly through skin". University of Warwick. https://www2.warwick.ac.uk/newsandevents/pressreleases/researchers_create_world146s/. Retrieved on October 16, 2016.
- ↑ "Medherant is developing a first-in-class transdermal drug delivery patch for prescription and OTC medicines". Medherant Ltd. https://http://www.medherant.co.uk/about-us. Retrieved on October 16, 2016.